​

Funding Round

Series A - Aerium Therapeutics

Series A - Aerium Therapeutics

Investment Firm

Overview

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Announced Date

Mar 22, 2022

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

Omega Funds

Omega Funds

Omega Funds is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed firm.

Participant Investors

2

Investor Name
Participant InvestorF-Prime Capital
Participant InvestorOmega Funds

Round Details and Background

Aerium Therapeutics raised an undisclosed amount on 2022-03-22 in Series A

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Company Funding History

1

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 22, 2022
Series A - Aerium Therapeutics
2-undefined

Recent Activity

There is no recent news or activity for this profile.